reboxetine has been researched along with anandamide in 1 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (anandamide) | Trials (anandamide) | Recent Studies (post-2010) (anandamide) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 2,566 | 29 | 957 |
| Protein | Taxonomy | reboxetine (IC50) | anandamide (IC50) |
|---|---|---|---|
| Fatty-acid amide hydrolase 1 | Homo sapiens (human) | 3.75 | |
| Potassium channel subfamily K member 3 | Homo sapiens (human) | 3 | |
| Potassium channel subfamily K member 2 | Bos taurus (cattle) | 1 | |
| Transient receptor potential cation channel subfamily V member 2 | Rattus norvegicus (Norway rat) | 4.78 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duarte, ID; Guzzo, LS; Resende, LC; Romero, TR | 1 |
1 other study(ies) available for reboxetine and anandamide
| Article | Year |
|---|---|
CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Dinoprostone; Endocannabinoids; Ethanolamines; Male; Morpholines; Norepinephrine; Pain Measurement; Palmitic Acids; Peripheral Nerves; Polyunsaturated Alkamides; Prazosin; Propranolol; Rats; Rats, Wistar; Reboxetine; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Sympathetic Nervous System; Yohimbine | 2013 |